VitsGen’s IND for Novel PSMA-Targeting Radioligand Therapy (177Lu-PSMA-VG01) in mCRPC Accepted by China’s CDE
VitsGen 21st Century Medicinal Chemistry Delivering Precision Radioligand Therapy
VitsGen CEO & CSO Invited Speakers at TRP US
Meeting VitsGen Therapeutics, Inc. at SNMMI 2024 Therapeutics Conference, Booth #13
In 2030 the overall 5-year survival rate for cancer would reach 46.6%
